Cesamet (Nabilone)
Synthetic THC approved for refractory chemotherapy nausea; off-label use varies in evidence strength.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Nabilone is a well-studied synthetic THC approved for one real job: treating chemo nausea when first-line drugs fail. It works, but modern antiemetics are often better. Off-label uses (pain, PTSD nightmares, MS spasticity) show promise in small trials but aren't proven yet. It will produce cannabis-like effects—sedation, dizziness, euphoria, sometimes anxiety—at therapeutic doses; individual responses vary. Not a miracle drug, but a legitimate tool when used correctly.
Plain-language summary
Nabilone (brand name Cesamet) is a laboratory-synthesized compound that activates the same cannabinoid receptors as THC, the main psychoactive component of cannabis. It was first developed by Eli Lilly and approved by the US FDA in 1985 [1].
Unlike whole-plant cannabis, nabilone comes as a single-molecule capsule with a fixed dose. Its only FDA-approved use is treating nausea and vomiting from chemotherapy when standard antiemetic drugs have failed or are not tolerated [1][2]. Physicians sometimes prescribe it off-label for chronic pain, PTSD-related nightmares, multiple sclerosis spasticity, and fibromyalgia—but evidence for these uses is limited to small or short-duration trials.
Because nabilone activates the same receptors as THC, it produces cannabis-like effects: drowsiness, dizziness, dry mouth, euphoria, and sometimes anxiety or depersonalization [1]. Effects on the individual vary. It is a Schedule II controlled substance in the United States.
> This is not medical advice. Nabilone is a prescription drug with known side effects, drug interactions, and contraindications. Any decision to start, stop, or change nabilone must be made with a physician who knows your complete medical history, current medications, and individual risk factors.
What probably works
Chemotherapy-induced nausea and vomiting (CINV)—refractory cases Strong evidence
A 2015 Cochrane systematic review found that nabilone and the related synthetic THC dronabinol were more effective than placebo for CINV and comparable in efficacy to older antiemetics such as prochlorperazine [2]. However, most of this evidence comes from trials conducted in the 1980s and early 1990s, before modern antiemetics became standard. Contemporary first-line agents—5-HT3 antagonists (ondansetron, palonosetron), NK1 antagonists (aprepitant, fosaprepitant), and corticosteroids—are generally more effective with fewer psychoactive side effects [3].
Current clinical guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) position nabilone as a second- or third-line option for CINV [3]. It is used when first-line agents fail or cause intolerable adverse effects. In 2024 chemotherapy protocols, nabilone is not a first-choice drug.
Bottom line: Nabilone works for chemotherapy nausea. It just isn't usually the best available tool anymore, but it remains a legitimate rescue option.
What might work
Chronic non-cancer pain Weak / limited
Small randomized controlled trials suggest modest pain reduction in neuropathic pain and fibromyalgia [4][5]. A 2008 placebo-controlled trial in 40 people with fibromyalgia found that nabilone reduced pain and anxiety over 4 weeks [5]. However, trial sample sizes are small, duration is short (typically 4–12 weeks), and dropout due to side effects is common. A 2015 systematic review of cannabinoids for chronic pain by the National Academies of Sciences, Engineering, and Medicine rated the overall evidence as low to moderate quality [6]. Effect sizes are small and heterogeneous across studies.
PTSD-related nightmares Weak / limited
A 2015 randomized, double-blind, placebo-controlled crossover trial in 10 Canadian military personnel with PTSD found that nabilone reduced nightmare frequency compared to placebo [7]. This is a promising signal but a very small study. Open-label case series from correctional populations also suggested symptomatic improvement, but these lack the methodological rigor of controlled trials. No large, definitive trial has been published.
Spasticity in multiple sclerosis Weak / limited
Some small controlled trials have reported symptomatic improvement in spasticity and pain in MS patients treated with nabilone [8]. Nabiximols (Sativex, a THC:CBD oral spray) has a larger body of MS-specific evidence. For spasticity in MS, the evidence base for nabilone specifically remains limited.
Anorexia and weight loss Weak / limited
Dronabinol (a different synthetic THC agonist) has more published data for appetite stimulation. Nabilone has been used in a similar way but the evidence is limited to small case series and open-label reports. No large randomized trials of nabilone for anorexia have been published.
What doesn't work or has weak evidence
Acute post-operative pain Disputed
A controlled trial in post-surgical patients found that nabilone increased pain scores compared to placebo or ketoprofen, suggesting potential harm rather than benefit [9]. Cannabinoids do not appear to be useful for acute surgical pain and may worsen it.
Anxiety as a primary treatment Weak / limited
While some patients report subjective anxiety relief from cannabis or cannabinoids, THC and its analogs exhibit a biphasic dose-response for anxiety [link:thc-dose-and-anxiety]. Low doses may reduce anxiety in some individuals; higher doses commonly increase anxiety, panic, and paranoia. No controlled evidence supports nabilone as a first-line anxiolytic, and its use in anxiety disorders carries meaningful risk of adverse psychiatric effects.
Sleep as a standalone indication Anecdote
Sedation is a common side effect of nabilone, but sedation is not the same as restful sleep. Chronic THC-agonist use can suppress REM sleep and disrupt sleep architecture over time, potentially worsening sleep quality with prolonged use despite initial sedation. No clinical evidence supports nabilone as an effective long-term sleep treatment.
Cancer treatment No data
Nabilone treats symptoms related to cancer treatment (chiefly nausea) but has no clinical evidence of anti-tumor activity. Claims that cannabinoids 'treat cancer' are not supported by clinical data and constitute marketing folklore.
What we don't know
- Long-term safety at therapeutic doses. Most published trials last 4–12 weeks. Data on safety beyond 6 months are sparse, and multi-year safety data do not exist for nabilone specifically.
- Optimal dosing for off-label indications. Published trials use widely varying dose regimens (e.g., 0.5–2 mg twice daily for pain, variable schedules for PTSD nightmares). No consensus dosing protocol exists, and no trial has systematically compared dose-response relationships.
- Head-to-head comparison with whole-plant cannabis or dronabinol. Almost no clinical trials directly compare nabilone to inhaled cannabis, oral cannabis oil, or dronabinol for the same indication. Claims that one is 'better' than another lack direct evidence.
- Drug interactions with modern psychiatric medications. Nabilone's interactions with selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and other contemporary psychotropic drugs are not well characterized in controlled trials.
- Whether individual variation in response can be predicted. Age, sex, genetics, and prior cannabis exposure may influence response and risk of adverse effects, but few studies have examined these variables systematically.
Comparison with standard treatments
For chemotherapy-induced nausea and vomiting: 5-HT3 antagonists (ondansetron, palonosetron), NK1 antagonists (aprepitant, fosaprepitant), and dexamethasone are first-line agents and generally more effective with fewer psychoactive side effects [3]. Nabilone is reserved for patients who fail or do not tolerate these options.
For neuropathic pain: Gabapentin, pregabalin, duloxetine, and tricyclic antidepressants have larger and longer evidence bases. Nabilone is not a first-line agent for peripheral neuropathy or post-herpetic neuralgia.
For MS spasticity: Baclofen and tizanidine remain the standard pharmacological treatments. Nabiximols (Sativex) has published evidence in MS spasticity in jurisdictions where it is available, with a larger trials base than nabilone alone.
For PTSD-related nightmares: Prazosin (an alpha-1 adrenergic antagonist) has been studied in PTSD nightmare disorder, though results are mixed. Trauma-focused psychotherapy—including cognitive processing therapy (CPT), prolonged exposure (PE), and eye-movement desensitization and reprocessing (EMDR)—remains the strongest evidence-based treatment for PTSD overall and is recommended before or alongside pharmacotherapy [link:thc-dose-and-anxiety].
Nabilone vs. medical cannabis flower or oil: Nabilone offers a predictable, single-molecule dose, potential insurance coverage in some jurisdictions, and a consistent pharmacokinetic profile. Whole-plant cannabis (smoked or vaporized) offers faster onset and lower cost in legal markets, but dose variability, and variable cannabinoid and terpene profiles. Neither is universally 'better'; choice depends on individual needs, legal status, and clinical goals.
Risks and side effects
Common side effects: Drowsiness, dizziness, dry mouth, euphoria, dysphoria, impaired coordination (ataxia), blurred vision, headache, and orthostatic hypotension [1].
Serious psychiatric effects (less common but significant): Hallucinations, paranoia, depersonalization, dissociation, and acute psychosis have been reported, especially at higher doses or in individuals with a personal or family history of psychotic illness [1]. These effects can be severe and frightening. Risk is higher in patients with schizophrenia, bipolar disorder, or psychotic spectrum conditions.
Cardiovascular effects: Tachycardia (elevated heart rate) and hypotension can occur and may be significant in older adults, patients with cardiac disease, or those taking cardiovascular medications. Blood pressure and heart rate monitoring may be warranted in at-risk populations.
Impairment: Nabilone impairs cognition, attention, and psychomotor function. Patients must not drive, operate machinery, or engage in safety-sensitive activities. Impairment can persist longer than the subjective 'high' due to accumulation and long half-lives of active metabolites.
Dependence and withdrawal: Chronic use of CB1 agonists produces tolerance and a cannabis-like withdrawal syndrome upon discontinuation, including irritability, sleep disturbance, and dysphoria.
Contraindications: Known hypersensitivity to cannabinoids. Use with extreme caution—or avoid—in patients with psychiatric history, cardiovascular disease, liver impairment, uncontrolled hypertension, or in the elderly at risk of falls [link:cannabis-and-falls-in-elderly].
Drug interactions: Additive CNS depression with alcohol, benzodiazepines, opioids, sedating antihistamines, and other central nervous system depressants. Nabilone is metabolized by hepatic cytochrome P450 enzymes; interactions with strong CYP inducers or inhibitors are possible [link:cannabis-and-polypharmacy-risks]. Concurrent use with other psychoactive drugs requires careful clinical monitoring.
> This is not medical advice. Individual risk depends on your health status, medications, psychiatric history, and age. A prescribing physician must perform a thorough assessment before initiating nabilone.
Sources
- Government U.S. Food and Drug Administration. Cesamet (nabilone) capsules prescribing information. Meda Pharmaceuticals, revised 2006.
- Peer-reviewed Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews. 2015;11:CD009464.
- Peer-reviewed Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. Journal of Clinical Oncology. 2020;38(24):2782–2797.
- Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
- Peer-reviewed Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. Journal of Pain. 2008;9(2):164–173.
- Peer-reviewed National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588.
- Peer-reviewed Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. Journal of Neurology. 2006;253(10):1337–1341.
- Peer-reviewed Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Canadian Journal of Anesthesia. 2006;53(8):769–775.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Falls in Elderly Adults — What the evidence says about cannabis, intoxication, and fall risk in adults 65+.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...